SOURCE: BioLife Remedies Inc.

March 20, 2007 16:23 ET

BioLife Remedies Inc. Announces the Evaluation on Two Products, Zotrol and Betatrol by LehmanBrown

GUANGZHOU, CHINA -- (MARKET WIRE) -- March 20, 2007 -- Bio Life Remedies, Inc. (PINKSHEETS: BLRS) announces today that LehmanBrown, an international accounting firm, had conducted an evaluation on the company based on two of its diabetic products, Zutrol™ and Betatrol™. The company's President and CEO, Jack Guo commented, "The value shown by the report is really an indication of the company's great potential; and I believe the company will grow rapidly as we build up the market channel and introduce more products to consolidate our product base."

The Report is now available on the official BioLife Website at: http://www.blfrproducts.com/.

About Bio Life Remedies, Inc

BIO LIFE REMEDIES, INC. combines Traditional Chinese Medicine and Western academic research and development practices with the newest scientific technology to produce effective medical and health-care products to combat serious diseases. The Bio Life Group has developed 108 master medical formulas to treat various diseases including diabetes, prostateria, osteoporosis, cerebrovascular disease, cardiac vascular disease, hypertension, menopausal syndrome, and sexual disorders in men and women.

Please visit http://www.blfrproducts.com for more information.

Forward-Looking Statements

You should not place undue reliance on forward-looking statements in this press release. This press release contains forward-looking statements that involve risks and uncertainties. Words such as "will," "anticipates," "believes," "plans," "goal," "expects," "future," "intends," and similar expressions are used to identify these forward-looking statements. Actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks we face as described in this press release.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information